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O44 rdves The purpose of our study was to determine whether
atpbw wdratsrlic agonist therapy could prevent neuurocardiogenk
amp
In pediatric patients
.
hckrwrnd
: Recent reports from adult patients suggest that
withdrawal of
alpl*ayirpathetk stimulation contributes to nem-
emeope,
MA&*. Sixteen young patients (mean age 13.1 years, range I
years 10 momthe to 17 ;bars 10 anonths) with recurrent syncope
mid a positive baseline hesd .up tilt response were studied . After a
positive baseline tilt response, pheaylephrine was Infused and
repeat tilt was performed for 30 thin or until the test result was
positive. At discharge, patients were followed up on a regimen of
oral peeadoephedrtme to evaluate treatment Jecdvenessand side
dfiMc s.
Raaaltr
. During baseline tit, seven patients experienced vase
.
depressor syncope, seven had mixed vasotkpressor-rardioinhtbf-
tory syncope and two had cardioinldbilory responses . All patients
became symptomatic, reproducing their clinical symplons
. Base-
lime mean arterial pressure decreased slightly Immediately on lilt
tag and significantly at the end point (82 t 13 vn . 77* 18 vs.
Neurocardiogenic syncope has been described in pediatric
and adult patients. It is characterized by sudden treament
loss of consciousness, hypotension, frequent bradycardia
and occasional asystole . Head-up tilt table testing has in-
creasingly become accepted as a tool for diagnosing neuro-
cardiogenic syncope and assessing pharmacologic maneu-
vers that prevent syncope (1-6) .
The exact pathophysiologic mechanism of neurocardio-
genic syncope is incompletely understood. It is postulated
that venodilation and venous pooling cause a decrease in
venous return, with a resultant decrease in stroke volume
.
Reflex increase in sympathetic activity occurs, resulting in
increased left ventricular contractility and heart rate
. This
increase in contractility in a relatively empty ventricle causes
activation of left ventricular mechanoreceptors called C fibers
.
Activation of these receptors causes reflex vagal activation and
trop
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PEDIATRIC CARDIOLOGY
30 *14 mm Hg, respectively, p < 0
.0001)
. Although heart rate
waded, the changes were not statistically significant (78 t 17 vs .
105* 19 vs. 87 ± 46 beatslmin, respectively, p = NS) . Phenyleph-
rine was Infused (mean 1 .74, range 0.6 to 3.0 pg/kg per min) as
patients underwent fallow-up tilt testing . Fifteen patients re-
mained asymptomatie without hemodynamic change; the remain-
lag patient manifested a blunted mixed response . During phe-
nykphrine Infusion, heart rate (64 t 12 vs. 81 s: 17 vs. 76 t
16 beets/min, respectively, p = NS) and mean arterial pressure
(96 d:
15 vs. 83 ± 19 vs. 80 ± 18 tam Hg, respectively, p = NS)
did not Change. Paring rdutpatlent oral rive treat-
ment (mean 11.7, range 6 to 14) 15 of 16 patients reported that
their clinical condition was controlled without side effects .
Cosclasi ms . Alpha-adrenergic stimulation prevents pediatric
neurocwrdlogenic syncope
. intravenous phenylephrine prevents
neurocardlogeac syncope during head-up tilt, despite relies vagal
bradycardia. Oral pseudoephedrine alleviates symptoms in pa-
tients with neurocardlogenic syncope without causing significant
side effects.
(J Am Coll Cardiol
1993
:22.594-7)
sympathoinhibition, leading to bradycardia and peripheral
vasodilation (7-10)
. These clinical findings may represent an
exaggerated form of the Bezold-larisch reflex (11 .12) .
Three recent studies (1,13,14) have demonstrated the
efficacy of alpha-adrenergic stimulation in preventing neuro-
cardiogenic syncope in adults. Sympathetic stimulation
causes an increase in vascular tone of the vascular smooth
muscle (9), which may prevent the venous pooling that
triggers the mechanism of neurocardiogenic syncope . The
purpose of our study was threefold: 1) to test whether the
intravenous alpha-adrenergic agonist phenylephrine could
eliminate neurocardiogenic syncope during head-up tilt test-
ing in pediatric patients, 2) to evaluate the usefulness of the
oral alpha-adreuet sic agonist pseudoephedrine during outpa-
tient treatment of pediatric neurocardiogenic syncope, and
3) to assess whether the immediate response to phenyleph-
rine infusion could predict the long-term response to oral
pseudoephedrine therapy.
Methods
Study patients
. Sixteen consecutive patients with a pos-
itive baseline head-up tilt test were included in this study .
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There were 10 females and 6 male patients with a mean age
of 13 .1 years (range 7 years 10 months to 17 years 10
months). All patients were referred for multiple episodes of
unexplained syncope and had normal findings on physical
examination and electrocardiogram (ECU) . Echocardiogra-
phy revealed normal findings in 14 patients, mitral valve
prolapse without mitral regurgitation in 1 patient and Eb-
stein's anomaly in I patient . One patient had a ventricular
pacemaker implanted 5 years previously for sinus bradycar-
dia with syncope . No patient was taking medication at the
time of study . The protocol was approved by the Institu-
tional Review Board of Emory University . Written informed
consent was obtained from all patients and their parents.
Head-up tilt . Tilt table testing was performed in the
morning after a clear liquid breakfast with no caffeine . No
s idation was administered . Continuous ECU monitoring
is performed and a peripheral intravenous line was started
for iifusoi,n of maintenance fluids . A percutaneous radial
arte i .1 line was inserted for constant blood pressure moni-
torin.. The patient was then allowed to rest in a quiet room
witho4' stimulation for 20 min . Head-up tilt testing was
perform td, utilizing an electric foot support tilt bed, tilting
the patient to an 80° upright position for 30 min or until the
test response was positive . A positive test response was
defined as vasodepressor, if there was a decrease in mean
arterial pressure >60% of baseline, cardioinhibitory, if
there was a sudden decrease in heart rate >50% or mixed
as a combination of vasodepressor and cardioinhibitory
responses .
After a positive baseline tilt response, the patient was
returned to the supine position . Phenylephrine was initially
infused at 0.5 ,LCglkg per min, and the dose incrementally
advanced until a 10 to 6 mm Hg increase in mean arterial
pressure was achieved and reflex bradycardia was noted .
Head-up tilt testing was repeated for 30 min or until the
response was positive .
Outpatient management . At discharge, patients began
treatment with pseudoephedrine (60 mg orally twice a day) .
A daily diary was maintained to record recurrent clinical
symptoms and side effects from pseudoephedrine . Ortho-
static blood pressure measurements were obtained at
follow-up visits. No routine follow-up head-up tilt testing
was performed .
Statistical analysis. Data are expressed as mean value ±
SD. Statistical analysis was performed using one-way anal-
ysis of variance (ANOVA) for repeated measures, compar-
ing supine values, initial tilt values and those at the tilt end
point. Post hoc testing was performed using the Fisher least
significant difference statistic to &termine the specific points
of difference. A p value < 0.05 was considered sifnifcant .
Results
Patients had a positive baseline tilt response at an average
time of 12.3 min (range I to 22). All patients became
symptomatic, reproducing clinical symptoms with hemody-
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Figure 1 . Individual patient heart rate (HR) changes during head-up
tilt table testing at baseline study (A) and with phenylephrine
infusion (B) . The abscissa represents time and the ordinate heart
rate. The first point (Supine) represents the heart rate measured with
the patient supine, the second (Tilt) immediately on tilt and the third
(End point) at the end point of the study, when the patient became
symptomatic. This end point occurred at a mean time of 12 .3 min,
range I to 22 in A compared with a mean time of 30 min in B . Heart
rate changes did not achieve significance during either the baseline
or the phenylephrine test . BPM = beats per minute .
namic changes . Seven patients had a pure vasodepressor
response, seven had a mixed cardioinhibitory and vasode-
pressor response and two had cardioinhibitory responses
with 15 and 6 s, respectively, of asystole .
Phenylephrine was infused at an average rate of
1.74 pglkg per min (range 0.6 to 3) . In
15 patients, the
infusion completely blocked the symptoms and syncopal
response noted during baseline head-up tilt .
One patient
manifesting a pure cardioinhibitory response at baseline
testing had a blunted mixed response, becoming presyncopal
at 22 min during follow-up phenylephrine
tilt evaluation .
The changes in heart rate are illustrated in Figure
1 .
During baseline testing, heart rate increased initially when
the patient was tilted from the supine position and the i
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Figure 2. Individual patient mean arterial blood pressure (MAP)
data points during head-up tilt testing at baseline study (A) and with
phenylephrine infusion (B). The abscissa represents time and the
onlhate mean arterial blood pressure. The first point (Supine)
represents mean arterial blood pressure with the patient supine, the
second (Tilt) immediately on tilt and the third (End point) at the end
point of the study, when the patient became symptomatic . This end
point occurred at a mean time of 12 .3 min, range I to 22 in
A, compared with a mean time of 30 min in B . During the baseline
test, blood pressure decreased significantly from the supine position
to the end point and from immediately on tilt to the end point .
During the phenylephrine test, there was an insignificant a.crease in
blood pressure from the supine position to immediately ei tilt ;
however, there was no huther decrease in blood pressure during the
remainder of the tilt test,
decreased slightly from immediate tilt to the end point of the
study (78 ± 17 vs. 105 ± 19 vs. 87 ± 46 beatslmin,
respectively; p = NS) (Fig. IA). A large standard deviation
was noted a;: the end point values, resulting from the
combination of vasodepressor, cardioinhibitory and mixed
responders.
During phenylephrine infusion, the same heart
rate trend was noted but to a lesser degree (64 ± 12 vs . 81 ±
17 vs. 76 ± 16 beats/min, respectively ; p = NS); however,
the standard deviations were much narrower (Fig . IB).
Figure 2 illustrates the changes in mean arterial blood
JACC Vol . 22, No . 2
August 1993:594-7
pressure during baseline and uhenylephrine head-up tilt
testing . Baseline supine mean arterial pressure decreased
slightly immediately on tilt and declined significantly at the
end point (82 ± 13 vs. 77 ± 18 vs. 30 ± 14 mm Hg,
respectively ; p < 0.0001) (Fig. 2A). Repeat tilt during
phenylephrine infusion blocked this hypotensive response .
Mean arterial pressure decreased slightly from the supine
position to tilt; however, there was no further decrease in
mean arterial pressure (96 ± 15 vs . 83 ± 19 vs. 80 ±
18 mm Hg, respectively ; p = NS) during the tilt (Fig . 2B) .
Outpatient follow-up on oral pseudoephedrine therapy for
an average of 11 .7 months (range 6 to 14) revealed that 15 of
16 patients reported themselves clinically "improved" (de-
fined as no recurrent syncope and a decrease in the fre-
quency of presyncopal episodes) or "cured" (no recurrent
syncopal or presyncopal episodes) . One patient who had a
negative tilt response while taking phenylephrine continued
to have recurrent syncope during treatment with pseudo-
ephedrine. She was later unsuccessfully treated with fludro-
cortisone (Florinef). beta-adrenergic blocking agents and a
combination of these agents . Her condition is currently
controlled with disopyramide. Most patients still demon-
strated orthostatic Wood pressure changes (<30 mm Hg)
without orthostatic complaints during office visits ; no hyper-
tension has been observed . No patient experienced any
pseudoephedrine side effects (that is, headaches, insomnia,
restlessness, tremors,
palpitation
or hypertension).
Discussion
Head-up tilt testing was recently proved effective for
reproducing clinical symptoms of presyncope and syncope
in pediatric patients with neurocardiogenic syncope . Several
studies (2,3,8,15,16) have demonstrated that it is relatively
sensitive, specific and reproducible for this diagnosis .
Various therapies have been attempted to eliminate this
syncopal response . Beta-blockers (4), mineralocorticoids
(18), disopyramide (19), anticholinergic agents (1) and pace-
makers (20) have been used in an attempt to prevent neuro-
cardiogenic syncope with varying degrees of success . Alpha-
adrenergic agents have been used successfully in adults .
Raviele et al. (1) demonstrated with tilt table testing that
syncope was eliminated in seven adults after the oral admin-
istration of an alpha-agonist (etilephrine) . Janosik et al . (13)
reported an 80% success rate using oral ephedrine in pre-
venting neurocardiogenic syncope during tilt table testing in
adultz. Most recently, Fouad-Tarazi et al . (14) demonstrated
that the experimental oral alpha-agonist midodrire increased
systolic blood pressure and improved ability to stand in eight
adults with neurocardiogenic syncope .
hhenylephriie is a powerful postsynaptic alpha-receptor
stimulator with very little effect on beta-adrenergic recep-
tors. It is known to increase vascular smooth muscle tone
and peripheral vascular resistance and to slightly increase
venous pressure (21) . i'his increase in sympathetic tone
shifts the circulatory pressure-volume curve so that at a
JACC Vol . 22. No. 2
August 1993 :594-7
steady intravascular volume, there is an increase in systemic
filling pressure (9). By preventing a decrease in preload, the
"empty" ventricle is avoided and activation of the left
ventricular mechanoreceptors is circumvented .
Oral pseudoephedrine has strong alpha- and some minor
beta-adrenergic effects . Theoretically, it will work by the
same mechanism as phenylephrine to prevent neurocardio-
genic syncope . Pseudoephedrine hat; potential advantages
over other treatment regimens for neurocardiogenic syn-
cope. Beta-blocker therapy has been reported to cause
depression, lethargy and difficulties with school performance
(17), whereas Florinef has been associated with weight gain,
peripheral edema and migraine headaches. Pseudoephedrine
is an over-the-counter medication with a low side effect
profile and is relatively inexpensive, resulting in ready
acceptance by both parents and patients .
Conclusions, This study demonstrates that vasodepres-
sor, cardioinhibitory and mixed neurocardiogenic syncopal
responses can be prevented in pediatric patients during
head-up tilt testing with the alpha-adrenergic agonist phe-
nylephrine . There is no increase in cardioinhibitory re-
sponse, despite an increase in vagal tone with phenyleph-
rine. The condition of patients with neurocardiogenic
syncope can be controlled in the outpatient setting with oral
pseudoephedrine, without significant side effects .
We speculate that alpha-adrenergic agonists prevent neu-
rocardiogenic syncope by one or two mechanisms . First,
through vesoconstriction, alpha-agonists may lessen venous
capacitance, thereby preventing venodilation and venous
pooling with its resultant decrease in preload . This effect is
similar to intravascular volume expansion with mineralocor-
ticoid therapy (18). Second, systemic hypotension may be
blocked by alpha-agonist arteriolar vasoconstriction, caus-
ing an increase in systemic vascular resistance . Future
studies are necessary to determine the exact hemodynamic
effects of alpha-adrenergic stimulation for the prevention of
neurocardiogenic syncope .
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